Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer

Catherine Oakman, Erica Moretti, Libero Santarpia, Angelo Di Leo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Fulvestrant is a pure estrogen antagonist that binds, blocks and downgrades the estrogen receptor (ER). Its unique mechanism of action is its antitumor activity after progression on prior endocrine therapy. Fulvestrant has shown activity in ER-dependent cells that are ligand independent. Fulvestrant has been approved at 250 mg/month for postmenopausal women with hormone-sensitive advanced breast cancer after progression or recurrence on antiestrogen therapy. The fulvestrant 500 mg regimen has just received approval by the EMA and the US FDA, supported by dose-dependent ER downregulation and the recent results of the clinical trial CONFIRM. Fulvestrant in combination with systemic lowering of estrogen has shown no improvement over fulvestrant alone. Combination therapy with inhibitors of growth factor signaling may have greater efficacy and is under exploration. To enhance the benefit of fulvestrant and improve outcomes for individuals with ER-positive breast cancer, greater understanding of resistance mechanisms is required. A key issue is identification of patients with ER-positive disease who retain sensitivity to antiestrogen therapy after progression on tamoxifen and/or aromatase inhibitors.

Original languageEnglish
Pages (from-to)173-186
Number of pages14
JournalFuture Oncology
Volume7
Issue number2
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Breast Neoplasms
Estrogen Receptors
Estrogen Receptor Modulators
Estrogen Antagonists
Aromatase Inhibitors
Tamoxifen
Therapeutics
fulvestrant
Intercellular Signaling Peptides and Proteins
Estrogens
Down-Regulation
Clinical Trials
Hormones
Ligands
Recurrence

Keywords

  • breast cancer
  • endocrine resistance
  • endocrine therapy
  • estrogen receptor blockade
  • fulvestrant

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer. / Oakman, Catherine; Moretti, Erica; Santarpia, Libero; Di Leo, Angelo.

In: Future Oncology, Vol. 7, No. 2, 02.2011, p. 173-186.

Research output: Contribution to journalArticle

Oakman, Catherine ; Moretti, Erica ; Santarpia, Libero ; Di Leo, Angelo. / Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer. In: Future Oncology. 2011 ; Vol. 7, No. 2. pp. 173-186.
@article{6a4f0a866d154aa08dd07a5ee9a34c47,
title = "Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer",
abstract = "Fulvestrant is a pure estrogen antagonist that binds, blocks and downgrades the estrogen receptor (ER). Its unique mechanism of action is its antitumor activity after progression on prior endocrine therapy. Fulvestrant has shown activity in ER-dependent cells that are ligand independent. Fulvestrant has been approved at 250 mg/month for postmenopausal women with hormone-sensitive advanced breast cancer after progression or recurrence on antiestrogen therapy. The fulvestrant 500 mg regimen has just received approval by the EMA and the US FDA, supported by dose-dependent ER downregulation and the recent results of the clinical trial CONFIRM. Fulvestrant in combination with systemic lowering of estrogen has shown no improvement over fulvestrant alone. Combination therapy with inhibitors of growth factor signaling may have greater efficacy and is under exploration. To enhance the benefit of fulvestrant and improve outcomes for individuals with ER-positive breast cancer, greater understanding of resistance mechanisms is required. A key issue is identification of patients with ER-positive disease who retain sensitivity to antiestrogen therapy after progression on tamoxifen and/or aromatase inhibitors.",
keywords = "breast cancer, endocrine resistance, endocrine therapy, estrogen receptor blockade, fulvestrant",
author = "Catherine Oakman and Erica Moretti and Libero Santarpia and {Di Leo}, Angelo",
year = "2011",
month = "2",
doi = "10.2217/fon.10.179",
language = "English",
volume = "7",
pages = "173--186",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer

AU - Oakman, Catherine

AU - Moretti, Erica

AU - Santarpia, Libero

AU - Di Leo, Angelo

PY - 2011/2

Y1 - 2011/2

N2 - Fulvestrant is a pure estrogen antagonist that binds, blocks and downgrades the estrogen receptor (ER). Its unique mechanism of action is its antitumor activity after progression on prior endocrine therapy. Fulvestrant has shown activity in ER-dependent cells that are ligand independent. Fulvestrant has been approved at 250 mg/month for postmenopausal women with hormone-sensitive advanced breast cancer after progression or recurrence on antiestrogen therapy. The fulvestrant 500 mg regimen has just received approval by the EMA and the US FDA, supported by dose-dependent ER downregulation and the recent results of the clinical trial CONFIRM. Fulvestrant in combination with systemic lowering of estrogen has shown no improvement over fulvestrant alone. Combination therapy with inhibitors of growth factor signaling may have greater efficacy and is under exploration. To enhance the benefit of fulvestrant and improve outcomes for individuals with ER-positive breast cancer, greater understanding of resistance mechanisms is required. A key issue is identification of patients with ER-positive disease who retain sensitivity to antiestrogen therapy after progression on tamoxifen and/or aromatase inhibitors.

AB - Fulvestrant is a pure estrogen antagonist that binds, blocks and downgrades the estrogen receptor (ER). Its unique mechanism of action is its antitumor activity after progression on prior endocrine therapy. Fulvestrant has shown activity in ER-dependent cells that are ligand independent. Fulvestrant has been approved at 250 mg/month for postmenopausal women with hormone-sensitive advanced breast cancer after progression or recurrence on antiestrogen therapy. The fulvestrant 500 mg regimen has just received approval by the EMA and the US FDA, supported by dose-dependent ER downregulation and the recent results of the clinical trial CONFIRM. Fulvestrant in combination with systemic lowering of estrogen has shown no improvement over fulvestrant alone. Combination therapy with inhibitors of growth factor signaling may have greater efficacy and is under exploration. To enhance the benefit of fulvestrant and improve outcomes for individuals with ER-positive breast cancer, greater understanding of resistance mechanisms is required. A key issue is identification of patients with ER-positive disease who retain sensitivity to antiestrogen therapy after progression on tamoxifen and/or aromatase inhibitors.

KW - breast cancer

KW - endocrine resistance

KW - endocrine therapy

KW - estrogen receptor blockade

KW - fulvestrant

UR - http://www.scopus.com/inward/record.url?scp=79952134296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952134296&partnerID=8YFLogxK

U2 - 10.2217/fon.10.179

DO - 10.2217/fon.10.179

M3 - Article

C2 - 21345137

AN - SCOPUS:79952134296

VL - 7

SP - 173

EP - 186

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 2

ER -